


# BIOGEN IDEC INC.

ISIN: US09062X1037 WKN: 09062X103 Asset Class: **Stock**

**Company** 2022/11/30 22:00:00



**Price**  
**305.17**  
USD

**Difference**  **4.72%(13.76)**



**Contact Details**

BIOGEN INC. Tel: 1-617-679-2000  
 -- Fax: -  
 225 Binney Street Web: <http://www.biogen.com>  
 02142 Cambridge E-mail: [info@biogen.com](mailto:info@biogen.com)

## Company Profile

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures                     | 2021           |                        | 2020           |                        | 2019           |                        |
|---------------------------------------|----------------|------------------------|----------------|------------------------|----------------|------------------------|
|                                       | Assets         | Liabilities and equity | Assets         | Liabilities and equity | Assets         | Liabilities and equity |
| <b>Current assets</b>                 | 7,856,500,000  |                        | 6,887,100,000  |                        | 8,381,800,000  |                        |
| <b>Common stock capital</b>           |                | 100,000                |                | 100,000                |                | 100,000                |
| <b>Fixed assets</b>                   | 16,020,800,000 |                        | 17,731,800,000 |                        | 18,852,500,000 |                        |
| <b>Equity capital of a company</b>    |                | 10,959,700,000         |                | 10,686,100,000         |                | 13,339,100,000         |
| <b>Cash and cash equivalents</b>      | 2,261,400,000  |                        | 1,331,200,000  |                        | 2,913,700,000  |                        |
| <b>Accrued liabilities</b>            |                | 0                      |                | 0                      |                | 0                      |
| <b>Other assets</b>                   | -              |                        | -              |                        | -              |                        |
| <b>Current liabilities</b>            |                | 4,298,200,000          |                | 3,742,200,000          |                | 4,863,800,000          |
| <b>Prepayments and accrued income</b> | -              |                        | -              |                        | -              |                        |
| <b>Non-current liabilities</b>        |                | 8,619,400,000          |                | 10,190,600,000         |                | 9,031,400,000          |
| <b>Different income</b>               |                | -                      |                | -                      |                | -                      |
| <b>Other liabilities</b>              |                | 1,320,500,000          |                | 1,329,600,000          |                | 1,348,900,000          |
| <b>Total assets</b>                   | 23,877,300,000 | 23,877,300,000         | 24,618,900,000 | 24,618,900,000         | 27,234,300,000 | 27,234,300,000         |

## Balance notes

|                            | 2021    | 2020    | 2019    |
|----------------------------|---------|---------|---------|
| <b>Accounting standard</b> | US-GAAP | US-GAAP | US-GAAP |
| <b>Employees</b>           | 9,610   | 9,100   | 7,400   |
| <b>Equity ratio</b>        | 46.17%  | 43.35%  | 48.96%  |
| <b>Debt-equity ratio</b>   | 116.61% | 130.69% | 104.23% |

## Others

|                         | 2021  | 2020   | 2019   |
|-------------------------|-------|--------|--------|
| <b>Tax Expense Rate</b> | 3.01% | 19.66% | 16.25% |

# BIOGEN IDEC INC.

ISIN: US09062X1037 WKN: 09062X103 Asset Class: **Stock**

## Income statement

|  | 2021           | 2020           | 2019           |
|--|----------------|----------------|----------------|
| <b>Turnover</b>  | 10,402,400,000 | 12,356,000,000 | 12,714,000,000 |
| <b>Net income</b>  | 1,556,100,000  | 4,000,600,000  | 5,888,500,000  |
| <b>EBIT</b>  | 1,952,446,860  | 5,109,003,900  | 7,005,021,660  |
| <b>Operating income before taxes</b>                                 | 1,745,200,000  | 5,047,500,000  | 7,125,900,000  |
| <b>Cash Flow</b>   | 3,639,900,000  | 4,229,800,000  | 7,078,600,000  |
| <b>Net interest income</b>   | -278,900,000   | -249,000,000   | -136,200,000   |
| <b>Research and development expenses</b>                             | 2,265,900,000  | 3,789,000,000  | 2,090,000,000  |
| <b>Income taxes</b>  | 52,500,000     | 992,300,000    | 1,158,000,000  |
| <b>Result from investments in subsidiaries, associates and other</b> | 34,900,000     | 5,300,000      | -79,400,000    |
| <b>Revenues per employee</b>   | 1,044,137      | 1,309,736      | 1,657,287      |

## Board of Directors

## Members of Management Board

|                      |                                |
|----------------------|--------------------------------|
| Stelios Papadopoulos | Chairman of Board of Directors |
| Alexander Denner     | Member of Board of Directors   |
| Eric Rowinsky        | Member of Board of Directors   |
| Maria Freire         | Member of Board of Directors   |
| Richard Mulligan     | Member of Board of Directors   |
| Stephen Sherwin      | Member of Board of Directors   |
| Caroline Dorsa       | Member of Board of Directors   |
| Jesus Mantas         | Member of Board of Directors   |
| William Hawkins      | Member of Board of Directors   |
| William Jones        | Member of Board of Directors   |
| Michel Vounatsos     | Chairman of Managing Board     |
| Ginger Gregory       | Member of Executive Committee  |
| Alphonse Galdes      | Member of Executive Committee  |
| Michael McDonnell    | Member of Executive Committee  |
| Rachid Izzar         | Member of Executive Committee  |
| Susan H. Alexander   | Member of Executive Committee  |